Attovia Therapeutics has completed an oversubscribed $90 million Series C financing, which the company plans to use along with existing cash and investments to advance its two lead pipeline candidates ...

The partners will use Cellino's autonomous biomanufacturing tech to produce high-quality autologous iPSCs for Karis' cardiovascular therapy.

Tolerogenic dendritic cells in the intestines are shown to reduce the immune responses caused by exposure to food proteins.

Research highlights the potential for modifying the chemical structures of psychedelics to produce analogues with improved efficacy and safety profiles.